drugset / Trial / NCT00963599

Montelukast in Seasonal Allergic Rhinitis - Fall 1999 Study (0476A-117)

NCT00963599

Phase 3 Completed 907 enrolled Organon and Co
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will evaluate the ability of oral montelukast/loratadine to improve the signs and symptoms of seasonal allergic rhinitis compared with loratadine alone, montelukast alone and placebo.

Timeline

Start
1999-09
Primary completion
1999-11
Completion
1999-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Loratadine Small molecule 10 mg Oral
Subject Montelukast Other / unclassified 10 mg Oral